Menu Back toGlobal Trends in Regulatory Reliance: Will the COVID-19 Experience Accelerate Implementation?

DIA 2021 Global Annual Meeting


Global Trends in Regulatory Reliance: Will the COVID-19 Experience Accelerate Implementation?

Session Chair(s)

Jayne C. Ware, MPH, MS

Jayne C. Ware, MPH, MS

  • Director Global Regulatory Policy
  • Merck & Co., Inc., United States
Explore growing trend of regulatory reliance, providing a global environmental scan of regulatory definitions and application of reliance policies. Feature perspectives on benefits and challenges to industry highlighting COVID-19 experiences.
Learning Objective : Reliance activities among regulators; IPRP's activities focusing on the result of the reliance survey.

Speaker(s)

Rebecca  Lumsden, PhD

An Industry Perspective on Regulatory Reliance Trends

Rebecca Lumsden, PhD

  • Director, Regulatory Policy and Intelligence
  • Pfizer Inc, United Kingdom
Lawrence  Liberti, PhD, RPh, RAC

Trends in Regulatory Reliance

Lawrence Liberti, PhD, RPh, RAC

  • Adjunct Research Professor
  • Temple University School of Pharmacy, Reg. Affairs and QA Grad Program, United States
Nobumasa  Nakashima, PhD

Examples of Reliance Activities Implemented by Regulators and Their Perspectives Based on The International Pharmaceutical Regulators Programme (IPRP) Studies

Nobumasa Nakashima, PhD

  • Associate Executive Director for International Programs
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan